Zacks Research Issues Pessimistic Forecast for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Zacks Research lowered their Q1 2025 earnings per share estimates for shares of Agilent Technologies in a research report issued on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $1.27 for the quarter, down from their previous estimate of $1.38. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Zacks Research also issued estimates for Agilent Technologies’ Q2 2025 earnings at $1.33 EPS, Q4 2025 earnings at $1.55 EPS, FY2025 earnings at $5.55 EPS, Q1 2026 earnings at $1.36 EPS, Q3 2026 earnings at $1.58 EPS and FY2026 earnings at $6.10 EPS.

Other equities research analysts have also recently issued research reports about the company. Wells Fargo & Company reduced their price objective on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. Barclays reduced their price target on shares of Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating for the company in a research report on Wednesday, November 27th. UBS Group upped their price objective on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. TD Cowen lifted their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Finally, Sanford C. Bernstein lowered their target price on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company. According to MarketBeat, Agilent Technologies presently has an average rating of “Hold” and an average price target of $143.62.

Agilent Technologies Stock Performance

Shares of A opened at $139.05 on Friday. Agilent Technologies has a one year low of $124.16 and a one year high of $155.35. The company has a market cap of $39.95 billion, a PE ratio of 31.45, a P/E/G ratio of 4.48 and a beta of 1.07. The stock has a 50-day moving average of $136.87 and a 200-day moving average of $136.60. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58.

Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.05. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The business had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same period in the prior year, the firm earned $1.38 earnings per share. Agilent Technologies’s revenue was up .8% on a year-over-year basis.

Agilent Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st will be paid a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date of this dividend is Tuesday, December 31st. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s dividend payout ratio is 22.40%.

Insider Activity

In related news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Agilent Technologies

Several large investors have recently modified their holdings of A. Crewe Advisors LLC raised its stake in shares of Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. Livelsberger Financial Advisory purchased a new stake in shares of Agilent Technologies in the third quarter worth about $28,000. Ridgewood Investments LLC purchased a new stake in shares of Agilent Technologies in the second quarter worth about $29,000. Ashton Thomas Securities LLC bought a new position in shares of Agilent Technologies in the third quarter valued at approximately $31,000. Finally, Fortitude Family Office LLC grew its stake in Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 95 shares in the last quarter. Hedge funds and other institutional investors own 87.42% of the company’s stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.